Journal of Shanghai Jiao Tong University (Medical Science) >

2022 , Vol. 42 >Issue 5: 680 - 684

DOI: https://doi.org/10.3969/j.issn.1674-8115.2022.05.018

Review

Research progress in acquired cystic disease-associated renal cell carcinoma

  • Han XIANG ,
  • Wu XIANG ,
  • Weiguo ZHANG
Expand
  • 1.Department of Radiology, Daping Hospital, Army Medical University, Chongqing 400042, China
    2.Department of Rehabilitation, Chongqing Beibei Traditional Chinese Medical Hospital, Chongqing 400799, China
ZHANG Weiguo, Email: wgzhang01@163.com.

Received date: 2022-01-17

  Accepted date: 2022-04-18

  Online published: 2022-05-28

Supported by

Fund of Chongqing Clinical Research Centre of Imaging and Nuclear Medicine(CSTC2015YFPT-gcjsyjzx0175)

Fold

Abstract

Acquired cystic disease-associated renal cell carcinoma (ACD-RCC) is the most common type of RCC seen in patients with end-stage renal disease and acquired cystic kidney disease, and was added to the list of RCC subtypes in the 2016 World Health Organization classification. ACD-RCC is generally believed to be indolent, however, some tumors may show local recurrence and distant metastasis. Periodic screening should be performed in dialysis patients, especially in younger patients with minor comorbidities, early detection and early intervention can improve the prognosis and quality of life. Literatures published at home and abroad mainly focused on it's clinicopathological features, there is scarce research describing the imaging appearance, prognosis and surveillance of ACD-RCC. This paper summarizes the epidemiology, etiology, pathological features, imaging manifestations, treatment, prognosis and surveillance of ACD-RCC, and aims to provide a compressive understanding of the disease for clinicians.

Key words： acquired cystic disease; renal cell carcinoma; image features; prognosis

Cite this article

Han XIANG , Wu XIANG , Weiguo ZHANG . Research progress in acquired cystic disease-associated renal cell carcinoma[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022 , 42(5) : 680 -684 . DOI: 10.3969/j.issn.1674-8115.2022.05.018

References

1 TICKOO S K, DEPERALTA-VENTURINA M N, HARIK L R, et al. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia[J]. Am J Surg Pathol, 2006, 30(2): 141-153.
2 PRZYBYCIN C G, HARPER H L, REYNOLDS J P, et al. Acquired cystic disease-associated renal cell carcinoma (ACD-RCC): a multiinstitutional study of 40 cases with clinical follow-up[J]. Am J Surg Pathol, 2018, 42(9): 1156-1165.
3 MOCH H, CUBILLA A L, HUMPHREY P A, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours[J]. Eur Urol, 2016, 70(1): 93-105.
4 INAMURA K. Renal cell tumors: understanding their molecular pathological epidemiology and the 2016 WHO classification[J]. Int J Mol Sci, 2017, 18(10): E2195.
5 FOSHAT M, EYZAGUIRRE E. Acquired cystic disease-associated renal cell carcinoma: review of pathogenesis, morphology, ancillary tests, and clinical features[J]. Arch Pathol Lab Med, 2017, 141(4): 600-606.
6 ISHIHARA H, YAMASHITA S, LIU Y Y, et al. Genetic and epigenetic profiling indicates the proximal tubule origin of renal cancers in end-stage renal disease[J]. Cancer Sci, 2020, 111(11): 4276-4287.
7 MEOLA M, SAMONI S, PETRUCCI I. Clinical scenarios in chronic kidney disease: kidneys' structural changes in end-stage renal disease[J]. Contrib Nephrol, 2016, 188: 131-143.
8 KALIL R S, LYNCH C F, ENGELS E A. Risk of cancer in retransplants compared to primary kidney transplants in the United States[J]. Clin Transplant, 2015, 29(10): 944-950.
9 TSUZUKI T, IWATA H, MURASE Y, et al. Renal tumors in end-stage renal disease: a comprehensive review[J]. Int J Urol, 2018, 25(9): 780-786.
10 SHAH A, LAL P, TOORENS E, et al. Acquired cystic kidney disease-associated renal cell in KMT2C and TSC2 genes[J]. Am J Surg Pathol, 2020, 44(11): 1479-1486.
11 FUSHIMI F, TAGUCHI K, IZUMI H, et al. Peroxiredoxins, thioredoxin, and Y-box-binding protein-1 are involved in the pathogenesis and progression of dialysis-associated renal cell carcinoma[J]. Virchows Arch, 2013, 463(4): 553-562.
12 HORI Y, ODA Y, KIYOSHIMA K, et al. Oxidative stress and DNA hypermethylation status in renal cell carcinoma arising in patients on dialysis[J]. J Pathol, 2007, 212(2): 218-226.
13 TOYOKUNI S. The origin and future of oxidative stress pathology: from the recognition of carcinogenesis as an iron addiction with ferroptosis-resistance to non-thermal plasma therapy[J]. Pathol Int, 2016, 66(5): 245-259.
14 CHEN T T, ACHAN A, WONG G. Acquired cystic disease-associated renal cell carcinoma[J]. Nephrology (Carlton), 2018, 23(7): 704-705.
15 KOJIMA F, GANDHI J S, MATSUZAKI I, et al. Comprehensive clinicopathologic analyses of acquired cystic disease-associated renal cell carcinoma with focus on adverse prognostic factors and metastatic lesions[J]. Am J Surg Pathol, 2020, 44(8): 1031-1039.
16 KURODA N, TAMURA M, HAMAGUCHI N, et al. Acquired cystic disease-associated renal cell carcinoma with sarcomatoid change and rhabdoid features[J]. Ann Diagn Pathol, 2011, 15(6): 462-466.
17 SRIGLEY J R, DELAHUNT B, EBLE J N, et al. The international society of urological pathology (ISUP) Vancouver classification of renal neoplasia[J]. Am J Surg Pathol, 2013, 37(10): 1469-1489.
18 KURODA N, YAMASHITA M, KAKEHI Y, et al. Acquired cystic disease-associated renal cell carcinoma: an immunohistochemical and fluorescence in situ hybridization study[J]. Med Mol Morphol, 2011, 44(4): 228-232.
19 CHRABA?SKA M, JAKUB R, BOGNA D. Bilateral and multifocal acquired cystic disease–associated renal cell carcinomas in patient with end-stage renal disease caused by systemic lupus erythematosus[J]. Int J Surg Pathol, 2021, 29(2): 198-204.
20 KATABATHINA V S, GARG D, PRASAD S R, et al. Cystic renal neoplasms and renal neoplasms associated with cystic renal diseases in adults: cross-sectional imaging findings[J]. J Comput Assist Tomogr, 2012, 36(6): 659-668.
21 EDO H, SUYAMA Y, SUGIURA H, et al. Acquired cystic disease-associated renal cell carcinoma extending to the renal pelvis mimicking urothelial carcinoma on computed tomography (CT): two case reports[J]. Am J Case Rep, 2020, 21: e926630.
22 BERKENBLIT R, RICCI Z, KANMANIRAJA D, et al. CT features of acquired cystic kidney disease-associated renal cell carcinoma[J]. Clin Imaging, 2022, 83: 83-86.
23 KITAJIMA K, YAMAMOTO S, KAWANAKA Y, et al. Imaging of renal cell carcinoma in patients with acquired cystic disease of the kidney: comparison 11 C-choline and FDG PET/CT with dynamic contrast-enhanced CT[J]. Jpn J Radiol, 2019, 37(2): 165-177.
24 AKITA H, JINZAKI M, AKITA A, et al. Renal cell carcinoma in patients with acquired cystic disease of the kidney: assessment using a combination of T2-weighted, diffusion-weighted, and chemical-shift MRI without the use of contrast material[J]. J Magn Reson Imaging, 2014, 39(4): 924-930.
25 KIM S Y, WOO S, HWANG S I, et al. Usefulness of resistive index on spectral Doppler ultrasonography in the detection of renal cell carcinoma in patients with end-stage renal disease[J]. Ultrasonography, 2014, 33(2): 136-142.
26 LEE S H, PARK J S, KIM H, et al. Glycolysis on F-18 FDG PET/CT is superior to amino acid metabolism on C-11 methionine PET/CT in identifying advanced renal cell carcinoma at staging[J]. Cancers (Basel), 2021, 13(10): 2381.
27 CIMADAMORE A, CHENG L, SCARPELLI M, et al. Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review[J]. Transl Androl Urol, 2021, 10(3): 1506-1520.
28 ROBILA V, KRAFT A O, SMITH S C. New entities, new technologies, new findings: a review of the cytologic features of recently established subtypes of renal cell carcinoma[J]. Cancer Cytopathol, 2019, 127(2): 79-97.
29 KURODA N, NARODA T, TAMURA M, et al. Acquired cystic disease-associated renal cell carcinoma: a clinicopathological study of seven cases[J]. Pol J Pathol, 2017, 68(4): 306-311.
30 BUTUROVI?-PONIKVAR J, VISNAR-PEROVIC A. Ultrasonography in chronic renal failure[J]. Eur J Radiol, 2003, 46(2): 115-122.
31 MEOLA M, PETRUCCI I. Ultrasound and color Doppler applications in chronic kidney disease[J]. G Ital Nefrol, 2012, 29(6): 699-715.
32 SIDHU P S, CANTISANI V, DIETRICH C F, et al. The EFSUMB guidelines and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) in non-hepatic applications: update 2017 (long version)[J]. Ultraschall Med, 2018, 39(2): e2-e44.
33 LIAKOPOULOS V, ELEFTHERIADIS T, MERTENS P R. Screening for renal cell carcinoma in dialysis patients[J]. Kidney Int, 2018, 94(6): 1238.
34 DAHLE D O, SKAUBY M, LANGBERG C W, et al. Renal cell carcinoma and kidney transplantation: a narrative review[J]. Transplantation, 2022, 106(1): e52-e63.
Options
Outlines

/

〈 〉